ESR1 and breast carcinoma: Researchers have employed various strategies to model hotspot ESR1 mutations in breast cancer cells, including genome editing approaches such as CRISPR/Cas9 or recombinant adeno-associated viral system (rAAV, 53.3%), and conventional ectopic overexpression (33.3%).